{"filings":[{"id":2586116,"accession_number":"0001193125-26-377485","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2026-09-01T11:05:15+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Upstream Bio announces Phase 3 plans for verekitug in severe asthma and CRSwNP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3: 400mg verekitug SC every 12 weeks vs placebo; one trial each in severe asthma and CRSwNP.","~1,500 patients total across both trials; broad populations, no biomarker restriction.","Primary endpoints: asthma AAER over 48 weeks; CRSwNP co-primary NPS and NCS at 48 weeks.","Trials to start Q1 2027; BLA submission expected with supportive results; potential launch as early as 2030.","Based on productive End-of-Phase 2 FDA meetings; data from 500+ treated patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2171523,"accession_number":"0001193125-26-343407","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2026-08-11T11:05:23+00:00","items":["2.02","9.01"],"status":"ready","headline":"Upstream Bio Q2 net loss $39.7M; cash $261.3M funds through 2027; Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.7M for Q2 2026 vs $40.0M year ago; R&D spend $36.1M, G&A $7.1M.","Cash and equivalents of $261.3M as of June 30, 2026, expected to fund operations through 2027.","Phase 3 trials in severe asthma and CRSwNP on track to initiate Q1 2027; FDA End-of-Phase 2 meetings on schedule.","Completed enrollment in Phase 2 VENTURE COPD trial (481 participants); data expected H2 2027.","Phase 2 data: ~80% of verekitug-treated CRSwNP patients achieved NPS improvement; ERS late-breaking data Sept 5-9."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":972639,"accession_number":"0001193125-26-265800","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2026-06-10T20:05:16+00:00","items":["5.07"],"status":"ready","headline":"Upstream Bio stockholders elect H. Edward Fleming and Liam Ratcliffe as Class II directors at 2026 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Both director nominees elected with over 40M votes for; Fleming received 40,715,035 for, Ratcliffe 43,812,021 for.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2026 approved 47,951,313 for, 143,251 against, 6,203 abstain.","Record date Apr 13, 2026; 54,419,986 shares outstanding, 48,100,767 represented at meeting (quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49964,"accession_number":"0001193125-26-220578","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2026-05-13T11:05:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Upstream Bio reports Q1 net loss $40.6M; Phase 3 plans on track for 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments $294.6M as of March 31, 2026; expected to fund operations through 2027.","Net loss $40.6M vs $27.3M YoY; R&D expenses $36.6M (up from $25.8M) driven by clinical and manufacturing costs.","End-of-Phase 2 meetings with FDA planned mid-2026; Phase 3 initiations in severe asthma and CRSwNP expected Q1 2027.","Phase 2 VENTURE COPD trial capping enrollment at >400 participants; data now expected H2 2027.","Phase 2 VALOUR LTE study in severe asthma completed enrollment with >90% retention of eligible patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":1034000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111892,"accession_number":"0001193125-26-126572","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Upstream Bio enters into $150M at-the-market offering agreement with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $150M of common stock through Leerink Partners as sales agent.","Agent will receive up to 3.0% commission on gross proceeds from sales.","Offering made under existing shelf registration statement; no obligation to sell any shares.","Sales may be made on Nasdaq or other markets as at-the-market offerings.","Company can suspend or terminate offering at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111891,"accession_number":"0001193125-26-125057","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Upstream Bio details Phase 3 strategy for verekitug; positive Phase 2 asthma and CRSwNP data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 development plan for verekitug: high-dose quarterly regimen (up to 400 mg q12w) in severe asthma and CRSwNP; initiation in Q1 2027.","Phase 2 VALIANT asthma trial met primary endpoint: AAER reduction 56% (p<0.0003) with 100 mg q12w; safety profile favorable.","Phase 2 VIBRANT CRSwNP data: placebo-adjusted NPS reduction -1.95 (WOCF) and NCS reduction -0.96 at week 24.","Cash position $341.5M as of Dec 31, 2025, expected to fund operations through 2027.","Q4 2025 net loss $42.5M vs $21.2M a year ago; R&D expenses rose to $40.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111890,"accession_number":"0001193125-26-045649","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Upstream Bio reports preliminary cash of $341.5M; Phase 2 VALIANT top-line data released","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Preliminary unaudited cash, cash equivalents and short-term investments of $341.5M as of Dec 31, 2025.","Top-line results from Phase 2 VALIANT trial of verekitug in severe asthma presented in webcast; details in investor presentation.","Year-end 2025 financial close not yet completed; full results to be included in Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111889,"accession_number":"0001193125-26-045500","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Upstream Bio reports positive Phase 2 VALIANT results: verekitug reduces asthma exacerbations by 56% and 39%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Verekitug 100 mg q12w reduced AAER by 56% (p<0.0003); 400 mg q24w reduced AAER by 39% (p<0.02) vs placebo.","Placebo-adjusted FEV1 improvement of 122 mL (q12w) and 139 mL (q24w) at week 60.","FeNO suppressed vs placebo by 20.4 ppb (q12w) and 26.3 ppb (q24w); mean reductions of 43-45% from baseline.","Verekitug well tolerated with safety consistent with prior studies; >90% of eligible patients rolled over to VALOUR LTE.","Company plans to advance verekitug into Phase 3 trials in severe asthma and CRSwNP after regulatory interactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128515,"accession_number":"0001193125-25-265705","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Upstream Bio Q3 loss $33.7M; VIBRANT Ph2 CRSwNP meets primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VIBRANT Ph2 met primary endpoint: placebo-adjusted NPS reduction of -1.8 (p<0.0001) at 24 weeks.","Key secondary endpoints met: 76% reduction in need for surgery/systemic corticosteroids (p=0.03).","Cash $372.4M as of Sept 30, 2025; expected to fund operations through 2027.","Net loss $33.7M vs $16.0M YoY; R&D expense rose to $33.0M from $15.4M on verekitug costs.","VALIANT Ph2 severe asthma top-line due Q1 2026; VENTURE Ph2 COPD enrollment ongoing."],"consensus_eps_estimate":-0.7898,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":2186000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145324,"accession_number":"0002022626-25-000005","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Upstream Bio Phase 2 VIBRANT trial meets primary endpoint for verekitug in CRSwNP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted reduction in nasal polyp score of -1.8 (p<0.0001) at Week 24; key secondary endpoint nasal congestion score reduced -0.8 (p=0.0003).","76% reduction in need for surgery or systemic corticosteroids (p=0.03); no serious adverse events observed.","Verekitug (100 mg every 12 weeks) generally well tolerated; company plans to engage regulators and present at upcoming medical conference.","Additional top-line data for verekitug in severe asthma expected in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145323,"accession_number":"0000950170-25-103528","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Upstream Bio Q2 net loss $40.0M; cash $393.6M; CRSwNP Phase 2 data on track for Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $40.0M in Q2 2025 vs. $14.7M in Q2 2024; R&D expense rose to $37.9M from $14.1M.","Cash, equivalents and short-term investments $393.6M as of June 30, 2025; expected to fund operations through 2027.","Phase 2 CRSwNP (VIBRANT) top-line data expected Q3 2025; severe asthma (VALIANT) enrollment complete, top-line Q1 2026.","First patient dosed in Phase 2 COPD trial (VENTURE) in July 2025; LTE study for severe asthma initiated May 2025.","General and administrative expenses $7.4M in Q2 2025, up from $4.0M in Q2 2024, driven by personnel and professional fees."],"consensus_eps_estimate":-0.6186,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":1503000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163719,"accession_number":"0000950170-25-085374","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Upstream Bio shareholders elect two Class I directors, ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Erez Chimovits received 42,089,191 votes for, 241,430 withheld; Marcella Kuhlman Ruddy received 41,993,308 for, 337,313 withheld.","Ratification of PwC as independent auditor for FY2025 approved with 43,600,758 for, 996 against, 25,541 abstain.","Meeting held June 10, 2025; 53,688,703 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163718,"accession_number":"0000950170-25-063954","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Upstream Bio Q1 net loss $27.3M; cash $431.4M; Phase 2 CRSwNP data on track for Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.3M in Q1 2025 vs $10.9M in Q1 2024; R&D expenses $25.8M (up $14.1M YoY).","Cash, equivalents and short-term investments $431.4M as of March 31, 2025, funding operations through 2027.","Phase 2 CRSwNP top-line data expected Q3 2025; Phase 2 severe asthma data now expected H1 2026.","First patient dosing in Phase 2 COPD trial expected mid-2025.","General and administrative expenses $6.8M vs $4.0M YoY, driven by personnel and professional fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":566000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181593,"accession_number":"0000950170-25-037619","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Upstream Bio posts Q4 net loss $21.2M; CRSwNP Ph2 enrollment complete; cash through 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $21.2M in Q4 2024 ($11.8M in Q4 2023); R&D expenses $21.8M vs $11.6M.","Completed enrollment in Phase 2 CRSwNP trial of verekitug; top-line data expected H2 2025.","Cash, equivalents and investments $470.5M as of Dec 31, 2024, funded by upsized IPO ($293M gross).","Phase 2 severe asthma data expected H2 2026; first COPD patient dosing on track for H2 2025.","Appointed Daniella Beckman to Board and Allison Ambrose as General Counsel in late 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198377,"accession_number":"0000950170-24-122784","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Upstream Bio Q3 net loss $16.0M; IPO raises $293M, extends cash runway through 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.0M in Q3 2024 vs $3.1M loss in Q3 2023, driven by higher R&D and G&A costs.","Cash, equivalents and short-term investments $220.7M at Sept 30, 2024; with IPO proceeds, runway through 2027.","Phase 2 trial of verekitug in severe asthma data expected H2 2026; CRSwNP data H2 2025; COPD trial starts H2 2025.","Upsized IPO raised ~$293M gross (17.25M shares at $17.00); Daniella Beckman appointed to board as independent director.","Phase 1b data showed verekitug 50% greater FeNO reduction vs tezepelumab; supports Q12W and Q24W dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":-18.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":1757000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198376,"accession_number":"0001193125-24-237580","cik":2022626,"company_name":"Upstream Bio, Inc.","ticker":"UPB","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Upstream Bio files amended charter and bylaws following IPO completion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorizes 500M shares of common stock and 10M shares of undesignated preferred stock.","Eliminates stockholder ability to act by written consent and call special meetings.","Establishes advance notice procedures for stockholder proposals and director nominations.","Amendments effective upon IPO completion on October 10 and October 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":436990000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}